The Antibody Response against HIV-1.

Neutralizing antibodies (NAbs) typically play a key role in controlling viral infections and contribute to the protective effect of many successful vaccines. In the case of HIV-1 infection, there is compelling data in experimental animal models that NAbs can prevent HIV-1 acquisition, although there is no similar data in humans and their role in controlling established infection in humans is also limited. It is clear HIV-specific NAbs drive the evolution of the HIV-1 envelope glycoprotein within an infected individual. The virus's ability to evade immune selection may be the main reason HIV-1 NAbs exert limited control during infection. The extraordinary antigenic diversity of HIV-1 also presents formidable challenges to defining NAbs that could provide broad protection against diverse circulating HIV-1 strains. Several new potent monoclonal antibodies (MAbs) have been identified, and are beginning to yield important clues into the epitopes common to diverse HIV-1 strains. In addition, antibodies can also act in concert with effector cells to kill HIV-infected cells; this could provide another mechanism for antibody-mediated control of HIV-1 replication. Understanding the impact of antibodies on HIV-1 transmission and pathogenesis is critical to helping move forward with rational HIV-1 vaccine design.

[1]  Jerome H. Kim,et al.  Human immunodeficiency virus vaccine trials. , 2012, Cold Spring Harbor perspectives in medicine.

[2]  N. Haigwood,et al.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones. , 2012, Cold Spring Harbor perspectives in medicine.

[3]  J. Mascola,et al.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. , 2011, Cold Spring Harbor perspectives in medicine.

[4]  E. Rosenberg,et al.  Epitopes Immediately below the Base of the V3 Loop of gp120 as Targets for the Initial Autologous Neutralizing Antibody Response in Two HIV-1 Subtype B-Infected Individuals , 2011, Journal of Virology.

[5]  C. Blish,et al.  The Breadth and Potency of Passively Acquired Human Immunodeficiency Virus Type 1-Specific Neutralizing Antibodies Do Not Correlate with the Risk of Infant Infection , 2011, Journal of Virology.

[6]  L. Morris,et al.  The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.

[7]  Feng Gao,et al.  Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. , 2011, Virology.

[8]  B. Chohan,et al.  HIV-1 superinfection and its implications for vaccine design. , 2010, Current HIV research.

[9]  D. Montefiori,et al.  Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. , 2010, The Journal of general virology.

[10]  W. Weissenhorn,et al.  Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41 , 2010, PLoS pathogens.

[11]  O. Pybus,et al.  B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection , 2010, Nature communications.

[12]  M. Sagar.  HIV-1 transmission biology: selection and characteristics of infecting viruses. , 2010, The Journal of infectious diseases.

[13]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[14]  C. Kankasa,et al.  Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. , 2010, Virology.

[15]  D. Venzon,et al.  Multiple Vaccine-Elicited Nonneutralizing Antienvelope Antibody Activities Contribute to Protective Efficacy by Reducing both Acute and Chronic Viremia following Simian/Human Immunodeficiency Virus SHIV89.6P Challenge in Rhesus Macaques , 2010, Journal of Virology.

[16]  E. Bunnik,et al.  Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. , 2010, The Journal of infectious diseases.

[17]  J. Kappes,et al.  GP41-Specific Antibody Blocks Cell-Free HIV Type 1 Transcytosis through Human Rectal Mucosa and Model Colonic Epithelium , 2010, The Journal of Immunology.

[18]  A MarioCalvo,et al.  Vaccination with ALVAC and AIDS-VAX to prevent HIV-1 infection in Thailand , 2010 .

[19]  J. Overbaugh,et al.  Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response. , 2010, Virology.

[20]  Q. Sattentau,et al.  Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals , 2010, PloS one.

[21]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[22]  Holly Janes,et al.  Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.

[23]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[24]  D. Dimitrov,et al.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens , 2009, Biochemical and Biophysical Research Communications.

[25]  L. Morris,et al.  Specificity of the autologous neutralizing antibody response , 2009, Current opinion in HIV and AIDS.

[26]  Lynn Morris,et al.  Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection , 2009, PLoS pathogens.

[27]  S. Gnanakaran,et al.  Escape from Autologous Neutralizing Antibodies in Acute/Early Subtype C HIV-1 Infection Requires Multiple Pathways , 2009, PLoS pathogens.

[28]  J. Binley.  Specificities of broadly neutralizing anti-HIV-1 sera , 2009, Current opinion in HIV and AIDS.

[29]  Lynn Morris,et al.  Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region , 2009, Journal of Virology.

[30]  Pascal Poignard,et al.  Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques , 2009, Nature Medicine.

[31]  Lynn Morris,et al.  Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? , 2009, Nature Medicine.

[32]  J. Baeten,et al.  Breadth of Neutralizing Antibody Response to Human Immunodeficiency Virus Type 1 Is Affected by Factors Early in Infection but Does Not Influence Disease Progression , 2009, Journal of Virology.

[33]  Lynn Morris,et al.  Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors , 2009, Journal of Virology.

[34]  I. Wilson,et al.  HIV-1 and influenza antibodies: seeing antigens in new ways , 2009, Nature Immunology.

[35]  C. Blish,et al.  Cross-Subtype Neutralization Sensitivity despite Monoclonal Antibody Resistance among Early Subtype A, C, and D Envelope Variants of Human Immunodeficiency Virus Type 1 , 2009, Journal of Virology.

[36]  H. Liao,et al.  Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers , 2009, AIDS.

[37]  Terri Wrin,et al.  Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.

[38]  A. Moreau,et al.  Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission. , 2009, Virology.

[39]  Richard T. Wyatt,et al.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.

[40]  Susan Moir,et al.  B cells in HIV infection and disease , 2009, Nature Reviews Immunology.

[41]  D. Venzon,et al.  Contribution of Nonneutralizing Vaccine-Elicited Antibody Activities to Improved Protective Efficacy in Rhesus Macaques Immunized with Tat/Env Compared with Multigenic Vaccines1 , 2009, The Journal of Immunology.

[42]  S. Zolla-Pazner,et al.  Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. , 2009, Molecular immunology.

[43]  E. Sandström,et al.  Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men , 2009, AIDS.

[44]  John R. Mascola,et al.  Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals , 2008, Journal of Virology.

[45]  Xuesong Yu,et al.  Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.

[46]  F. Pereyra,et al.  Continuous Viral Escape and Selection by Autologous Neutralizing Antibodies in Drug-Naïve Human Immunodeficiency Virus Controllers , 2008, Journal of Virology.

[47]  D. Montefiori,et al.  Correlation of Vaccine-Elicited Systemic and Mucosal Nonneutralizing Antibody Activities with Reduced Acute Viremia following Intrarectal Simian Immunodeficiency Virus SIVmac251 Challenge of Rhesus Macaques , 2008, Journal of Virology.

[48]  J. Mascola,et al.  Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies , 2008, Journal of Virology.

[49]  Vicki C. Ashley,et al.  Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia , 2008, Journal of Virology.

[50]  B. Chohan,et al.  Human Immunodeficiency Virus Type 1 Superinfection Occurs despite Relatively Robust Neutralizing Antibody Responses , 2008, Journal of Virology.

[51]  Lynn Morris,et al.  Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C , 2008, Journal of Virology.

[52]  R. Desrosiers,et al.  Importance of the V1/V2 Loop Region of Simian-Human Immunodeficiency Virus Envelope Glycoprotein gp120 in Determining the Strain Specificity of the Neutralizing Antibody Response , 2008, Journal of Virology.

[53]  S. Hammer,et al.  HIV Vaccine Research: The Way Forward , 2008, Science.

[54]  E. Sanders-Buell,et al.  Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. , 2008, Virology.

[55]  Hanneke Schuitemaker,et al.  Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.

[56]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[57]  R. Kaul,et al.  HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers , 2008, AIDS.

[58]  Terri Wrin,et al.  Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. , 2008, The Journal of infectious diseases.

[59]  J. Sodroski,et al.  The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus , 2008, Nature Reviews Microbiology.

[60]  G. Landucci,et al.  FcγRIIa Genotype Predicts Progression of HIV Infection1 , 2007, The Journal of Immunology.

[61]  A. Trkola,et al.  In Vivo Efficacy of Human Immunodeficiency Virus Neutralizing Antibodies: Estimates for Protective Titers , 2007, Journal of Virology.

[62]  D. Burton,et al.  Fc receptor but not complement binding is important in antibody protection against HIV , 2007, Nature.

[63]  P. Gilbert,et al.  Recombinant gp120 Vaccine-Induced Antibodies Inhibit Clinical Strains of HIV-1 in the Presence of Fc Receptor-Bearing Effector Cells and Correlate Inversely with HIV Infection Rate1 , 2007, The Journal of Immunology.

[64]  S Gnanakaran,et al.  Clade-Specific Differences between Human Immunodeficiency Virus Type 1 Clades B and C: Diversity and Correlations in C3-V4 Regions of gp120 , 2007, Journal of Virology.

[65]  Douglas D. Richman,et al.  Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors , 2007, Journal of Virology.

[66]  Hui Li,et al.  Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.

[67]  Jun Li,et al.  Antiviral Antibodies Are Necessary for Control of Simian Immunodeficiency Virus Replication , 2007, Journal of Virology.

[68]  Tongqing Zhou,et al.  Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.

[69]  A. MacNeil,et al.  Comparison of Heterologous Neutralizing Antibody Responses of Human Immunodeficiency Virus Type 1 (HIV-1)- and HIV-2-Infected Senegalese Patients: Distinct Patterns of Breadth and Magnitude Distinguish HIV-1 and HIV-2 Infections , 2007, Journal of Virology.

[70]  D. Richman,et al.  Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. , 2006, Virology.

[71]  F. Bibollet-Ruche,et al.  Role of V1V2 and Other Human Immunodeficiency Virus Type 1 Envelope Domains in Resistance to Autologous Neutralization during Clade C Infection , 2007, Journal of Virology.

[72]  A. Trkola,et al.  Complement Lysis Activity in Autologous Plasma Is Associated with Lower Viral Loads during the Acute Phase of HIV-1 Infection , 2006, PLoS medicine.

[73]  Feng Gao,et al.  Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa , 2006, Journal of Virology.

[74]  Karina Yusim,et al.  Role of Maternal Autologous Neutralizing Antibody in Selective Perinatal Transmission of Human Immunodeficiency Virus Type 1 Escape Variants , 2006, Journal of Virology.

[75]  Christos J. Petropoulos,et al.  Neutralizing Antibody Responses against Autologous and Heterologous Viruses in Acute versus Chronic Human Immunodeficiency Virus (HIV) Infection: Evidence for a Constraint on the Ability of HIV To Completely Evade Neutralizing Antibody Responses , 2006, Journal of Virology.

[76]  S. Brunet,et al.  Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1. , 2006, The Journal of infectious diseases.

[77]  J. Overbaugh,et al.  Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. , 2006, AIDS research and human retroviruses.

[78]  Thomas C. Quinn,et al.  Neutralizing Antibodies Do Not Mediate Suppression of Human Immunodeficiency Virus Type 1 in Elite Suppressors or Selection of Plasma Virus Variants in Patients on Highly Active Antiretroviral Therapy , 2006, Journal of Virology.

[79]  Barbra A. Richardson,et al.  Neutralization Escape Variants of Human Immunodeficiency Virus Type 1 Are Transmitted from Mother to Infant , 2006, Journal of Virology.

[80]  Yang Liu,et al.  Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[81]  Bette Korber,et al.  Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.

[82]  Robyn L Stanfield,et al.  Antibody vs. HIV in a clash of evolutionary titans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[83]  R. Ruprecht,et al.  Antibodies: can they protect against HIV infection? , 2005, Current drug targets. Infectious disorders.

[84]  Dorothy M. Lang,et al.  Selection for Human Immunodeficiency Virus Type 1 Envelope Glycosylation Variants with Shorter V1-V2 Loop Sequences Occurs during Transmission of Certain Genetic Subtypes and May Impact Viral RNA Levels , 2005, Journal of Virology.

[85]  Michael G Hudgens,et al.  Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. , 2005, The Journal of infectious diseases.

[86]  D. Venzon,et al.  Vaccine-Elicited Antibodies Mediate Antibody-Dependent Cellular Cytotoxicity Correlated with Significantly Reduced Acute Viremia in Rhesus Macaques Challenged with SIVmac2511 , 2005, The Journal of Immunology.

[87]  S. Buchbinder,et al.  Human Immunodeficiency Virus Type 1 (HIV-1) Diversity at Time of Infection Is Not Restricted to Certain Risk Groups or Specific HIV-1 Subtypes , 2004, Journal of Virology.

[88]  Kimberly C. Brouwer,et al.  Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection , 2004, AIDS.

[89]  S. Zolla-Pazner,et al.  The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection , 2004, Journal of Virology.

[90]  R. Doms,et al.  HIV Transmission , 2004, The Journal of experimental medicine.

[91]  Bette T. Korber,et al.  Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission , 2004, Science.

[92]  J. Baeten,et al.  Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population , 2004, AIDS.

[93]  Wayne A Hendrickson,et al.  Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[94]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[95]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[96]  D. Montefiori,et al.  Effect of Humoral Immune Responses on Controlling Viremia during Primary Infection of Rhesus Monkeys with Simian Immunodeficiency Virus , 2003, Journal of Virology.

[97]  John P. Moore,et al.  Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site , 2003, Journal of Virology.

[98]  J. Clements,et al.  Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. , 2002, AIDS research and human retroviruses.

[99]  D. Montefiori,et al.  Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa , 2002, Journal of Virology.

[100]  C. Cheng‐Mayer,et al.  Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.

[101]  E. Daar,et al.  Antibody from Patients with Acute Human Immunodeficiency Virus (HIV) Infection Inhibits Primary Strains of HIV Type 1 in the Presence of Natural-Killer Effector Cells , 2001, Journal of Virology.

[102]  G. Landucci,et al.  Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. , 2001, AIDS research and human retroviruses.

[103]  L. Heyndrickx,et al.  Identification and characterization of sera from HIV‐infected individuals with broad cross‐neutralizing activity against group M (env clade A–H) and group O primary HIV‐1 isolates , 2000, Journal of medical virology.

[104]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[105]  Tahir A. Rizvi,et al.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[106]  L. Sánchez-Pulido,et al.  Molecular analysis of HIV‐1 gp120 antibody response using isotype IgM and IgG phage display libraries from a long‐term non‐progressor HIV‐1‐infected individual , 1999, European journal of immunology.

[107]  A Muñoz,et al.  A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. , 1999, The Journal of infectious diseases.

[108]  J. Mascola,et al.  Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.

[109]  N. Haigwood,et al.  Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.

[110]  J. Mascola,et al.  Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. , 1998, The Journal of infectious diseases.

[111]  J. Goudsmit,et al.  Neutralizing antibodies are positively associated with CD4+ T‐cell counts and T‐cell function in long‐term AIDS‐free infection , 1998, AIDS.

[112]  D. Thea,et al.  Neutralizing antibody and perinatal transmission of human immunodeficiency virus type 1. New York City Perinatal HIV Transmission Collaborative Study Group. , 1998, AIDS research and human retroviruses.

[113]  E. Fenyö,et al.  Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. , 1997, The Journal of infectious diseases.

[114]  D. Neau,et al.  Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients. , 1997, AIDS research and human retroviruses.

[115]  D. Montefiori,et al.  Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. , 1997, The Journal of infectious diseases.

[116]  J. Overbaugh,et al.  Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies , 1997, Journal of virology.

[117]  H. Fleury,et al.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals , 1997, Journal of virology.

[118]  H. Katinger,et al.  The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate , 1996, Journal of virology.

[119]  S. J. Clark,et al.  HIV-specific cellular and humoral immune responses in primary HIV infection. , 1996, AIDS research and human retroviruses.

[120]  B. Walker,et al.  Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. , 1996, AIDS research and human retroviruses.

[121]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[122]  B. Korber,et al.  Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes , 1996, Journal of virology.

[123]  B. Chohan,et al.  Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1 , 1995, Journal of virology.

[124]  G. Berke.  Unlocking the secrets of CTL and NK cells. , 1995, Immunology today.

[125]  D. Venzon,et al.  Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype. , 1995, The Journal of pediatrics.

[126]  D. Ho,et al.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. , 1995, The New England journal of medicine.

[127]  J. Levy,et al.  Features of HIV-1 that could influence maternal-child transmission. , 1994, JAMA.

[128]  J. Moore,et al.  Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1 , 1994, Journal of virology.

[129]  H Hengartner,et al.  Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. , 1994, Science.

[130]  E. Halapi,et al.  Neutralizing antibodies and viral characteristics in mother‐to‐child transmission of HIV‐1 , 1993, AIDS.

[131]  D. Ho,et al.  Genotypic and phenotypic characterization of HIV-1 patients with primary infection. , 1993, Science.

[132]  J. Albert,et al.  Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. , 1993, The Journal of infectious diseases.

[133]  E. Holmes,et al.  Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection , 1993, Journal of virology.

[134]  A. Saah,et al.  Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[135]  J. Overbaugh,et al.  Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques , 1992, Journal of virology.

[136]  B. Korber,et al.  Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. , 1992, Science.

[137]  W. Schleif,et al.  Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody , 1992, Nature.

[138]  J Overbaugh,et al.  Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS , 1991, Journal of virology.

[139]  K. Murthy,et al.  Prevention of HIV infection by passive immunization with HIV immunoglobulin. , 1991, AIDS research and human retroviruses.

[140]  P. Johnson,et al.  The genetic fate of molecularly cloned simian immunodeficiency virus in experimentally infected macaques. , 1991, Virology.

[141]  R. Desrosiers,et al.  Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys , 1991, Journal of virology.

[142]  R. Herberman,et al.  Lymphocyte-mediated cytotoxicity. , 1987, Pediatric annals.

[143]  J. Baeten,et al.  HIV-1 neutralizing antibody breadth is affected by factors early in infection, but does not influence disease progression. Journal of Virology 83(10):10269-74 , 2009 .

[144]  G. Landucci,et al.  FcgammaRIIa genotype predicts progression of HIV infection. , 2007, Journal of immunology.

[145]  J. Overbaugh,et al.  Gender differences in HIV-1 diversity at time of infection , 2000, Nature Medicine.

[146]  J. Levy,et al.  Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. , 1998, Blood.

[147]  D. Montefiori,et al.  Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. , 1996, The Journal of infectious diseases.